Registry of Asian patients with myeloproliferative neoplasms
Asian Myeloproliferative Neoplasm (MPN) Registry - An Asian Myeloid Working Group (AMWG) Project.
This study is collecting information from Asian patients with myeloproliferative neoplasms to learn more about their condition and how different treatments work for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT05882773 on ClinicalTrials.gov |
What this trial studies
This observational cohort registry collects data on patients diagnosed with myeloproliferative neoplasms (MPN) across multiple centers in Asia. It includes both prospective and retrospective data collection, focusing on clinicopathologic, cytogenetic, and mutational characteristics, as well as treatment responses and outcomes. Patients diagnosed between 2010 and 2025 will be monitored through routine clinic visits and medical record reviews, with data collected at diagnosis and approximately every six months thereafter. The aim is to establish a comprehensive clinical registry to better understand MPN in the Asian population.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with specific types of myeloproliferative neoplasms according to the 2017 WHO classification.
Not a fit: Patients diagnosed with myelodysplastic syndrome or chronic myeloid leukaemia BCR-ABL1 positive will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of MPN in Asian patients, leading to improved treatment strategies and outcomes.
How similar studies have performed: While there have been various studies on MPN, this registry approach focusing specifically on the Asian population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years old at the time of diagnosis of MPN. 2. Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification): 1. Polycythaemia vera 2. Essential thrombocythemia 3. Primary myelofibrosis, pre-fibrotic/early stage 4. Primary myelofibrosis, overt fibrotic stage 5. Post-polycythaemia vera myelofibrosis 6. Post-essential thrombocythaemia myelofibrosis 7. MPN-unclassifiable 3. All subjects need to provide informed consent. Exclusion Criteria: A subject will not be eligible if he/she meets any of the following criteria: 1\. Subject was diagnosed with myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, or chronic myeloid leukaemia BCR-ABL1 positive, under the 2017 WHO classification
Where this trial is running
Hong Kong
- Department of Medicine, Queen Mary Hospital — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Harinder Gill, MD — The University of Hong Kong
- Study coordinator: Harinder Gill, MD
- Email: gillhsh@hku.hk
- Phone: +852 22554542
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.